Resource Summary Report

Generated by PRECISE-TBI on Jul 30, 2026

Prize4Life

RRID:SCR_006558
Type: Tool

Proper Citation

Prize4Life (RRID:SCR_006558)

Resource Information

URL: http://www.prize4life.org/

Proper Citation: Prize4Life (RRID:SCR_006558)

Description: Prize4Life is a 501(c)(3) nonprofit organization dedicated to accelerating the discovery of treatments and cures for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig"s disease). Our mission is to accelerate the discovery of a treatment and a cure for ALS by using powerful incentives to attract new people and new ideas and to leverage existing efforts and expertise in the ALS field. Our Values: * Patients first. Avichai Kremer, one of the Harvard Business School students who founded Prize4Life, was diagnosed with ALS in 2004. We therefore know the disease firsthand and have a sense of urgency to find a treatment. We value patients and their viewpoints. Patients, please tell us what you think. * Global awareness. We plan to push ALS to the forefront of fatal disease issues. We need your help in order to do this. Get involved. * New people and new ideas. We believe important breakthroughs in ALS may reside in the minds and laboratories of people who are not currently researching the disease. Our platform is a bridge for reaching these people. Enter the competition. * Results. Research is traditionally funded upfront, before an idea is even tested. Our prize model ensures that only clear research results, vetted by a team of scientific advisors, are rewarded. grants; funding resource;.

Synonyms: Prize4Life

Resource Type: data or information resource, topical portal, funding resource, portal

Resource Name: Prize4Life

Resource ID: SCR_006558

Alternate IDs: nif-0000-00493

Record Creation Time: 20220129T080236+0000

Record Last Update: 20260729T044137+0000

Ratings and Alerts

No rating or validation information has been found for Prize4Life.

No alerts have been found for Prize4Life.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at PRECISE-TBI .

Dandl S, et al. (2024) Heterogeneous treatment effect estimation for observational data using model-based forests. Statistical methods in medical research, 33(3), 392.

Cox LM, et al. (2022) The microbiota restrains neurodegenerative microglia in a model of amyotrophic lateral sclerosis. Microbiome, 10(1), 47.

Gordon J, et al. (2019) Insights into Amyotrophic Lateral Sclerosis from a Machine Learning Perspective. Journal of clinical medicine, 8(10).

Karanevich AG, et al. (2018) Using an onset-anchored Bayesian hierarchical model to improve predictions for amyotrophic lateral sclerosis disease progression. BMC medical research methodology, 18(1), 19.

Hilton JB, et al. (2017) CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord. Scientific reports, 7, 42292.

Huang Z, et al. (2017) Complete hazard ranking to analyze right-censored data: An ALS survival study. PLoS computational biology, 13(12), e1005887.

Ong ML, et al. (2017) Predicting functional decline and survival in amyotrophic lateral sclerosis. PloS one, 12(4), e0174925.

Borel F, et al. (2016) Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. Human gene therapy, 27(1), 19.

Williams JR, et al. (2016) Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD. Neurobiology of disease, 89, 1.

Xu X, et al. (2015) A natural human IgM that binds to gangliosides is therapeutic in murine models of amyotrophic lateral sclerosis. Disease models & mechanisms, 8(8), 831.